AML with FLT-3 mutation is treated by :
High-Yield Explanation
Gilteritinib inhibits FMS like tyrosine Kinase 3 (FLT-3) and hence used in the treatment of AML with FLT-3 mutation.
Related Pharmacology MCQs
Which of the following is glucocoicoid synthesis inhibitor?
General
At a high altitude of 3000 m, a person complains of breathlessness. All of the following can...
General
All of the following drugs act on cell membrane except:
General
A non-competitive inhibitor of an enzyme?
General
Which of the following is a phase I metabolic reaction?
General